The patients began treatment with oral sirolimus; after 1 year of treatment, there was improvement in exertional dyspnea in all 3 patients. HealthDay News — Sirolimus may be beneficial for patients ...
Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results